Tag: GLP-1 / glucagon dual receptor agonist

  • Mazdutide

    GLP-1 / glucagon dual receptor agonist

    A long-acting dual GLP-1 and glucagon receptor agonist; under development for obesity and type 2 diabetes.

    Abstract

    Mazdutide (IBI362, LY3305677; modified peptide with glucagon backbone and GLP-1 modifications; molecular weight approximately 4500 Da) is a dual GLP-1/glucagon receptor agonist developed by Eli Lilly and out-licensed to Innovent Biologics for development in China. The compound is structurally and mechanistically similar to cotadutide and oxyntomodulin, with C18 fatty acid extension for once-weekly dosing. Phase 2 trials in type 2 diabetes and obesity demonstrated dose-dependent HbA1c reduction and weight loss comparable to or exceeding semaglutide at higher dose tiers. Phase 3 trials are ongoing in China (DREAMS program) and US. The dual mechanism produces increased energy expenditure (glucagon effect) on top of the GLP-1 appetite suppression. Used as a reference long-acting dual GLP-1/glucagon agonist.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cotadutide

    GLP-1 / glucagon dual receptor agonist

    A dual GLP-1 and glucagon receptor agonist; investigated for type 2 diabetes, NASH, and obesity.

    Abstract

    Cotadutide (MEDI0382; CAS 2125247-22-1; modified peptide with glucagon backbone and GLP-1 modifications; approximately 30 amino acid peptide with C16 fatty acid extension; molecular weight approximately 4140 Da) is a dual GLP-1/glucagon receptor agonist developed at AstraZeneca for type 2 diabetes, non-alcoholic steatohepatitis (NASH), and obesity. The compound is a balanced co-agonist (approximately 5:1 GLP-1:glucagon ratio at receptor). The GLP-1 component drives glucose-dependent insulin secretion, glucagon suppression, and appetite reduction; the glucagon component independently increases hepatic fatty acid oxidation, energy expenditure, and lipolysis. Phase 2 trials demonstrated superior weight loss and HbA1c reduction compared to GLP-1 monoagonists at matched dose, with hepatic fat reduction supporting the NASH indication. Plasma half-life supports once-daily subcutaneous dosing; phase 3 development is ongoing. Used as a reference dual GLP-1/glucagon agonist in metabolic research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.